Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
How would you treat an SCLC patient who manifests a bona fide etoposide allergy on cycle two day one?
Answer from: Medical Oncologist at Community Practice
Perhaps consider desensitizing; other options include trying irinotecan or paclitaxel in place of Etoposide.
Sign In
or
Register
to read more
7325
Related Questions
When, if at all, do you utilize neoadjuvant chemotherapy alone for resectable, Stage II NSCLC with mutations such as EGFR or ALK?
Would you offer immunotherapy to a patient with stage II NSCLC with an EGFR exon 20 mutation?
Would you switch from carboplatin/etoposide to cisplatin/etoposide in an LS-SCLC patient who initially declines cisplatin but subsequently agrees to it?
How would you approach the management of a patient with stage IIIA lung adenocarcinoma and multifocal hepatocellular carcinoma with Child-Pugh A cirrhosis?
How do you approach duration of immunotherapy in patients with metastatic NSCLC?
What are your treatment options and preferences for classical EGFR mutated NSCLC upon widespread progression following first line chemo/osimertinib?
Would you consider adjuvant osimertinib for NSCLC with an EGFR E746_S752delinsV exon 19 mutation?
Is concurrent immuno-radiation therapy a viable treatment option for patients with unresectable, non-metastatic, locally advanced lung cancer, who have high PD-L1 expression and no oncogenic mutations?
For a patient with NSCLC harboring an EGFR or ALK mutation that transforms into SCLC, would you add immunotherapy to chemotherapy or avoid immunotherapy given the tumor's EGFR/ALK origin?
Would you change systemic therapy in a patient with SCLC with stable systemic disease but CNS progression?